NEWS not from the

New Post Public Reply Private Reply Replies (1) Message Board
moxaman
330
NEWS not from the company.

https://ih.advfn.com/p.php?pid=nmona&arti...ymbol=OWCP


OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., is conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development and improvement of strains of medical cannabis specifically designed for the treatment of several illnesses/medical conditions.


OWC has also entered into an agreement with Mediq Innovation Partners for marketing OWC's topical psoriasis cream in Germany. OWC has also progressed on using specific dosages of its Cannabaniod-based products administered through soluble pills taken orally, with its initial focus on PTSD, multiple myeloma and topical treatment of burns in addition to psoriasis.


OWCP shares have recently consolidated and are currently trading at $.40 per share.


FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.


COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Company has not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing the press release and for hosting the full analyst report on Traders News Source website.


NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 240

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 956

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 471

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 251

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 366

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 98

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 597

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 289

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Future Leaders: Vantage Partners with AIESEC

Updated Category News Views 285

Vantage as a Platinum Partner of AIESEC FHN Vantage is proud to highlight its inspirational collaboration with AIESEC FHN, a partnership dedicated to empowering youth leadership development. This initiative significantly impacted the career trajectories of numerous young individuals seeking growth within a competitive landscape. The Mission of AIESEC AIESEC stands as a...

Continue Reading
Nicox Reports Strong Q4 2024 Financial Performance and Outlook

Updated Category News Views 140

Nicox Excels in Fourth Quarter Financial Performance Nicox SA, an international ophthalmology company known for its innovative solutions, has unveiled its financial performance for the fourth quarter of 2024. The results reflect the company's resilience and strategic direction as it continues to navigate the complexities of the ophthalmic landscape. Key Financial...

Continue Reading
International Paper's Strategic Move to Acquire DS Smith in Europe

Updated Category News Views 193

International Paper's New Acquisition Strategy International Paper, a prominent player in the packaging industry based in the United States, has recently achieved a significant milestone by receiving the European Union's approval for its acquisition of DS Smith, a UK competitor. This strategic move, valued at approximately $7.2 billion, comes as part of International...

Continue Reading
Market Movements: Futures, Debates and GameStop's Trends

Updated Category News Views 251

Markets Today: Futures, Debate Fallout, and Sector Shifts Stock futures are drifting lower as traders weigh two things at once: upcoming US inflation data and a combative debate between presidential candidates Donald Trump and Kamala Harris. The exchange was lively—lots of heat, fewer specifics—leaving investors still hunting for clear economic plans. Meanwhile,...

Continue Reading
Trogenix Launches Innovative Cancer Treatment Platform to Save Lives

Updated Category News Views 123

Trogenix: A Revolutionary Approach to Cancer Treatment In the rapidly evolving domain of cancer therapies, Trogenix Ltd has emerged with a groundbreaking platform designed to transform cancer treatment, especially for aggressive forms like glioblastoma. Originating from the innovative research of the University of Edinburgh, Trogenix is on a mission to elevate the...

Continue Reading